Statement of Principles concerning familial adenomatous polyposis No. 40 of 2013

Administered by Department of Veterans' Affairs

Legislation au F2013L01127 Not in force Legislative Instrument

Legislation content

REPATRIATION MEDICAL AUTHORITY

 

INSTRUMENT NO. 40 of 2013

 

VETERANS’ ENTITLEMENTS ACT 1986

MILITARY REHABILITATION AND COMPENSATION ACT 2004

 

EXPLANATORY NOTES FOR TABLING

 

 

  1. The Repatriation Medical Authority (the Authority), under subsection 196B(8) of the Veterans’ Entitlements Act 1986 (the VEA), revokes Instrument No. 61 of 2002, determined under subsection 196B(3) of the VEA concerning familial adenomatous polyposis.

 

2.             The Authority is of the view that on the sound medical-scientific evidence available it is more probable than not that familial adenomatous polyposis and death from familial adenomatous polyposis can be related to particular kinds of service.  The Authority has therefore determined pursuant to subsection 196B(3) of the VEA a Statement of Principles, Instrument No. 40 of 2013 concerning familial adenomatous polyposis.  This Instrument will in effect replace the revoked Statement of Principles.

 

3.             The provisions of the Military Rehabilitation and Compensation Act 2004 (the MRCA) relating to claims for compensation commenced on 1 July 2004.  Claims under section 319 of the MRCA for acceptance of liability for a service injury sustained, a service disease contracted or service death on or after 1 July 2004 are determined by the Military Rehabilitation and Compensation Commission by reference to Statements of Principles issued by the Authority pursuant to the VEA.

 

4.             The Statement of Principles sets out the factors that must exist, and which of those factors must be related to the following kinds of service rendered by a person:

 

 eligible war service (other than operational service) under the VEA;

 defence service (other than hazardous service and British nuclear test defence service) under the VEA;

 peacetime service under the MRCA,

 

before it can be said that, on the balance of probabilities, familial adenomatous polyposis or death from familial adenomatous polyposis is connected with the circumstances of that service.

 

5.             This Instrument results from an investigation notified by the Authority in the Government Notices Gazette of 30 June 2010 concerning familial adenomatous polyposis in accordance with section 196G of the VEA.  The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.

 

6.             The contents of this Instrument are in similar terms as the revoked Instrument.  Comparing this Instrument and the revoked Instrument, the differences include:

 

  • adopting the latest revised Instrument format, which commenced in 2005;
  • revising the definition of 'relevant service' in clause 6; and
  • specifying a date of effect for the Instrument in clause 8.

 

7.             Further changes to the format of the Instrument reflect the commencement of the MRCA and clarify that pursuant to subsection 196B(3A) of the VEA, the Statement of Principles has been determined for the purposes of both the VEA and the MRCA.

 

8.             Prior to determining this Instrument, the Authority advertised its intention to undertake an investigation in relation to familial adenomatous polyposis in the Government Notices Gazette of 30 June 2010, and circulated a copy of the notice of intention to investigate to a wide range of organisations representing veterans, service personnel and their dependants.  The Authority invited submissions from the Repatriation Commission, organisations and persons referred to in section 196E of the VEA, and any person having expertise in the field.  No submissions were received for consideration by the Authority during the investigation.

 

9.             This instrument is compatible with the Human Rights and Freedoms recognised or declared in the International Instruments listed in Section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011. A Statement of Compatibility with Human Rights follows.

 

10.         The determining of this Instrument finalises the investigation in relation to familial adenomatous polyposis as advertised in the Government Notices Gazette of 30 June 2010.

 

11.         A list of references relating to the above condition is available to any person or organisation referred to in subsection 196E(1)(a) to (c) of the VEA.  Any such request must be made in writing to the Repatriation Medical Authority at the following address:

 

The Registrar

Repatriation Medical Authority

GPO Box 1014

BRISBANE    QLD    4001

Statement of Compatibility with Human Rights

(Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011)

 

Instrument No.:   Statement of Principles No. 40 of 2013

Kind of Injury, Disease or Death: Familial adenomatous polyposis

 

This Legislative Instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.

Overview of the Legislative Instrument

1. This Legislative Instrument is determined pursuant to subsection 196B(8) of the Veterans' Entitlements Act 1986 (the VEA) for the purposes of the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).

2. This Legislative Instrument:-

  • facilitates claimants in making, and the Repatriation Commission in assessing, claims under the VEA and the MRCA respectively, by specifying the circumstances in which medical treatment and compensation can be extended to eligible persons who have familial adenomatous polyposis;
  • facilitates the review of such decisions by the Veterans' Review Board and the Administrative Appeals Tribunal;
  • outlines the factors which the current sound medical-scientific evidence indicates must exist before it can be said that, on the balance of probabilities, familial adenomatous polyposis is connected with the circumstances of eligible service rendered by a person, as set out in clause 4 of the Explanatory Notes;
  • replaces Instrument No. 61 of 2002; and
  • reflects developments in the available sound medical-scientific evidence concerning familial adenomatous polyposis which have occurred since that earlier instrument was determined. 

3. The Instrument is assessed as being a technical instrument which improves the medico-scientific quality of outcomes under the VEA and the MRCA. 

Human Rights Implications

4. This Legislative Instrument does not derogate from any human rights. It promotes the human rights of veterans, current and former Defence Force members as well as other persons such as their dependents, including:

  • the right to social security (Art 9, International Covenant on Economic, Social and Cultural Rights; Art 26, Convention on the Rights of the Child and Art 28, Convention on the Rights of Persons with Disabilities) by helping to ensure that the qualifying conditions for the benefit are 'reasonable, proportionate and transparent'[1];
  • the right to an adequate standard of living (Art 11, ICSECR; Art 27, CRC and Art 28, CRPD) by facilitating the assessment and determination of social security benefits;
  • the right to the enjoyment of the highest attainable standard of physical and mental health (Art 12, ICSECR and Art 25, CRPD), by facilitating the assessment and determination of compensation and benefits in relation to the treatment and rehabilitation of veterans and Defence Force members; and
  • the rights of persons with disabilities by facilitating the determination of claims relating to treatment and rehabilitation (Art 26, CRPD).

Conclusion

This Legislative Instrument is compatible with human rights as it does not derogate from and promotes a number of human rights.

 

Repatriation Medical Authority

 

 

 

 

 

 

[1] In General Comment No. 19 (The right to social security), the Committee on Economic, Social and Cultural Rights said (at paragraph 24) this to be one of the elements of ensuring accessibility to social security.

Overview

The Repatriation Medical Authority Instrument No. 40 of 2013 was enacted in 2013 to address the issue of determining the connection between familial adenomatous polyposis and certain types of service rendered by individuals, as required under the Veterans’ Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004. This legislative instrument was developed by the Repatriation Medical Authority under the authority granted by the Veterans’ Entitlements Act 1986, and its primary policy objective is to facilitate the assessment and determination of claims for compensation and medical treatment related to familial adenomatous polyposis, ensuring that the qualifying conditions for benefits are reasonable, proportionate, and transparent. The instrument replaced a previous Statement of Principles concerning familial adenomatous polyposis, reflecting developments in the available medical-scientific evidence since the previous instrument was determined. The new instrument specifies the factors that must exist, and be related to particular types of service, before it can be said that familial adenomatous polyposis is connected with the circumstances of that service.

Scope and Application

The Repatriation Medical Authority Instrument No. 40 of 2013, concerning familial adenomatous polyposis, applies to veterans, current and former defence force members, and their dependants who may be eligible for medical treatment and compensation under the Veterans’ Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004. This legislative instrument facilitates claimants in making and the Repatriation Commission in assessing claims for conditions connected to eligible service, including eligible war service, defence service, and peacetime service. The instrument sets out the factors that must exist, and which of those factors must be related to the service, before it can be said that familial adenomatous polyposis or death from the condition is connected with the circumstances of that service. This Instrument replaces Instrument No. 61 of 2002 and reflects the latest medical-scientific evidence. It is compatible with human rights as it does not derogate from and promotes the rights of veterans, current and former Defence Force members, and other persons, such as their dependents, by facilitating the assessment and determination of social security benefits and ensuring access to treatment and rehabilitation. The instrument's provisions are consistent with international human rights standards, including the right to social security, the right to an adequate standard of living, and the right to the highest attainable standard of physical and mental health.

Key Provisions

The Repatriation Medical Authority, under subsection 196B(8) of the Veterans' Entitlements Act 1986, has revoked Instrument No. 61 of 2002 concerning familial adenomatous polyposis and has issued a new Statement of Principles, Instrument No. 40 of 2013, based on the latest medical-scientific evidence. This new Instrument identifies the factors that must exist, and be related to specific kinds of service, before it can be said that, on the balance of probabilities, familial adenomatous polyposis or death from familial adenomatous polyposis is connected with the service circumstances. These kinds of service include eligible war service, defence service, and peacetime service as defined under the Veterans' Entitlements Act and the Military Rehabilitation and Compensation Act 2004. The Statement of Principles outlines the obligations of claimants and the Repatriation Commission in assessing claims for medical treatment and compensation related to familial adenomatous polyposis. It specifies the evidence required to establish a connection between the condition and the service rendered, thus guiding both the claimants and the Commission in their respective roles. Additionally, the Instrument facilitates the review of decisions made by the Veterans' Review Board and the Administrative Appeals Tribunal, ensuring a transparent and fair process for all parties involved. Failure to comply with the provisions of this Instrument may result in the denial of claims for compensation. The Authority has determined that there are no offences or penalties explicitly stated for breaches of this Instrument. However, the implications of non-compliance could lead to the rejection of claims for treatment and compensation, impacting the rights and benefits of veterans and service personnel under both the Veterans' Entitlements Act and the Military Rehabilitation and Compensation Act. The Instrument ensures compatibility with human rights, promoting the rights to social security, an adequate standard of living, and the highest attainable standard of physical and mental health, as recognised in international human rights instruments. By facilitating the assessment and determination of benefits related to familial adenomatous polyposis, the Instrument supports the human rights of veterans, current and former Defence Force members, and their dependents, ensuring that the qualifying conditions for benefits are reasonable, proportionate, and transparent.

Legal classification tags

Area of Law
Veterans Law
Instrument
Regulation
Concepts
Definitions & Interpretation
Repeal & Amendment
Licensing & Registration
Compliance Obligations
Human Rights Law

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.